Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, ISSN: 0304-419X, Vol: 1878, Issue: 4, Page: 188914
2023
- 6Citations
- 21Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- Captures21
- Readers21
- 21
Review Description
Pancreatic cancer (PC) is characterized by ( epi )genetic and microenvironmental alterations that negatively impact the treatment outcomes. New targeted therapies have been pursued to counteract the therapeutic resistance in PC. Aiming to seek for new therapeutic options for PC, several attempts have been undertaken to exploit BRCA1/2 and TP53 deficiencies as promising actionable targets. The elucidation of the pathogenesis of PC highlighted the high prevalence of p53 mutations and their connection with the aggressiveness and therapeutic resistance of PC. Additionally, PC is associated with dysfunctions in several DNA repair-related genes, including BRCA1/2, which sensitize tumours to DNA-damaging agents. In this context, poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) were approved for mutant BRCA1/2 PC patients. However, acquired drug resistance has become a major drawback of PARPi. This review emphasizes the importance of targeting defective BRCAs and p53 pathways for advancing personalized PC therapy, with particular focus on how this approach may provide an opportunity to tackle PC resistance.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0304419X2300063X; http://dx.doi.org/10.1016/j.bbcan.2023.188914; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85162883366&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37201730; https://linkinghub.elsevier.com/retrieve/pii/S0304419X2300063X; https://dx.doi.org/10.1016/j.bbcan.2023.188914
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know